ABSTRACT
As a leading complication of sepsis, sepsis-induced cardiac dysfunction (SICD) contributed to the high mortality of patients with sepsis. Long non-coding RNA (LncRNA) LINC00472 has been reported to be in sepsis-induced disease. Nonetheless, its biological function and underlying molecular in SICD remain largely unknown. In this study, in vivo and in vitro SICD models were established via LPS treatment. H&E staining was employed for the evaluation of myocardial injury. ELISA assay was performed to detect cardiac Troponin I (cTnI), creatine kinase-MB (CK-MB), interleukin (IL)-1β, and tumor necrosis factor-α (TNF-α) levels. Cardiomyocyte viability and apoptosis were assessed via CCK-8 and flow cytometry assays. The transcriptional regulation of YY1 on LINC00472 was demonstrated via ChIP assay. Besides, the interaction between YY1 and LINC00472, as well as the association between miR-335-3p and LINC00472 or MAOA were verified via luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Herein, highly expressed LINC00472 was observed in both in vivo and in vitro SICD models. LINC00472 knockdown substantially attenuated LPS-induced inhibition on cardiomyocyte viability and reversed cardiomyocyte apoptosis and inflammatory response mediated by LPS treatment. YY1 induced LINC00472 upregulation, thereby promoting cardiomyocyte dysfunction induced by LPS. In addition, MAOA upregulation or miR-335-3p inhibition could partly reverse the suppressive effect on LPS-induced cardiomyocyte dysfunction mediated by LINC00472 knockdown. Based on our results, it seemed that YY1-activated LINC00472 might contribute to SICD progression via the miR-335-3p/MAOA pathway.

Introduction
As a systemic inflammatory syndrome (SIRS) triggered by aberrant host responses to invasive infection [1,2], sepsis could cause cardiac dysfunction (CD), a pervasive complication occurring during sepsis [3]. About 60% of patients with sepsis may develop cardiac dysfunction, which is also known as sepsis-induced cardiac dysfunction (SICD); moreover, sepsis patients with SICD exhibit a much higher mortality rate (70%-90%), compared with those without SICD (20%) [4,5]. Although extensive research has been done in the past few decades, SICD-associated molecular mechanisms remain largely abstruse [6]. Hence, therapeutic strategies to restore cardiac function are essential to the improvement of the survival rate of SICD patients.

There are a variety of mechanisms applied to explain SICD, including inflammation, mitochondrial energy, metabolic disorders, apoptosis, and oxidative stress [7,8]. Lipopolysaccharide (LPS)-activated septic myocardial injury and cardiomyocyte dysfunction have been widely adopted for both in vivo and in vitro models [9]. Previous studies have demonstrated that cardiomyocyte apoptosis plays a critical role in SICD pathogenesis [10]. Pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β, were used as vital indicators for inflammatory responses of cardiomyocytes in SICD [11]. Therefore, the suppression on apoptosis and inflammatory responses of cardiomyocytes might be a feasible therapeutic strategy for SICD treatment.
Long non-coding RNAs (lncRNAs) are defined as a category of non-protein-coding RNAs with over 200 nts in length [12]. LncRNAs are deeply involved in a series of physiological processes, such as cell differentiation, proliferation, apoptosis, and autophagy [12,13]. In addition, lncRNAs also participate in the regulation of inflammatory responses in diverse diseases [14]. Recently, the functional importance of lncRNAs in regulating sepsis-induced myocardial injury and cardiomyocyte function has been extensively investigated. For instance, Sun et al. found lncRNA KCNQ1OT1 alleviated SICD by regulating XIAP via miR-192-5p [15]. Chen et al. revealed that lncRNA CYTOR ameliorated SICD by targeting miR-24/XIAP pathway [16]. Shan et al. disclosed H19 inhibited SICD progression via the miR-93-5p/SORBS2 cascade [17]. As reported in a previous study by Li et al., high LINC00472 expression was observed in sepsis-associated liver injury and exacerbated its progression via the miR-373-3p/TRIM8 pathway [18], suggesting the promoting role of LINC00472 in sepsis-induced organ injury. Nevertheless, whether LINC00472 is implicated in SICD remains obscure.

In this work, we studied the role of LINC00472 and the potential regulatory network involved in the in vitro SICD model. It was assumed that YY1-mediated LINC00472 could accelerate LPS-induced cardiomyocyte dysfunction by regulating cardiomyocyte viability, apoptosis, and inflammatory responses via the miR-335-3p/MAOA axis. Our findings may provide novel insights into SICD development and progression.

Materials and methods

Murine model

16 male C57BL/6 J mice (7 to 9 weeks old) bought from Beijing Vital River Laboratory Animal Technology Corporation were randomly assigned to the Control group (n = 8) and the LPS group (n = 8). SICD was induced in mice via intraperitoneal injection of LPS (5 mg/kg). All the mice were sacrificed about 12 h after injection [19]. Then, heart samples and serum samples were collected for following experiments. All the procedures of the animal study were permitted by the Ethics Committee of Affiliated Hospital of Guangdong Medical University.

Hematoxylin and eosin (H&E) staining

According to the standard procedures, fresh myocardial tissues isolated from mice were fixed with 4% paraformaldehyde (PFA), embedded in paraffin, sectioned, and then stained via H&E Staining Kit (Abcam, USA). Finally, the tissue structures were observed via a microscope [20].

Enzyme-linked immunosorbent assay (ELISA)

The concentrations of Creatine kinase-MB (CK-MB) and cardiac Troponin I (cTnI) in serum were measured via corresponding commercial kits (Nanjing Jiancheng). The levels of TNF-α and IL-1β in serum and cell supernatant were detected via respective ELISA Kits (Thermofisher) [21].

Western blotting

Total protein was isolated from tissue samples or cells via RIPA kit (Beyotime, China) and measured for protein concentration by BCA method. Subsequently, protein samples were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore, USA). Thereafter, the membranes were blocked in buffer (5% skim milk), and cultured with the primary antibody (against cleaved Caspase-3 levels, Bcl-2, MAOA, or GAPDH) and the HRP-conjugated secondary antibody. The protein bands were visualized by enhanced chemiluminescence (ECL) kit (Amersham Biosciences, UK) [22].

RT-qPCR

Total RNA was isolated by Trizol (Invitrogen) and subject to reverse transcription via Transcriptor First Strand cDNA Synthesis Kit (Roche, Germany) for cDNA synthesis. Then, qPCR was performed on C1000 Thermal Cycler (Bio-Rad, CA) with FastStart Universal SYBR Green Master (Roche). Relative gene expression was determined by the $2^{-\Delta\Delta Ct}$ method [23]. The applied primers
were listed below: LINC00472: 5′-GATGAGCAG CGGTCTCCTCC-3′ (forward) and 5′-GGGCC TCTGAGCCCTCTCTCC-3′ (reverse); YY1: 5′-ATG GCCTCGGGGGGACACC-3′ (forward) and 5′- TCACCTGGTT GTTTTTGGGC-3′ (reverse); MAO A: 5′-ACAGGGCCTCCTGAAGAAG-3′ (forward) and 5′-GAACGGACGCTCCATTCGGA-3′ (reverse); GAPDH: 5′-ACCACCTCCTCCACCTTTG AC-3′ (forward) and 5′-TGTGCTGAGCCAAA TTCGTT-3′ (reverse); miR-335-3p: 5′-CAAGAG CAATAACGAAAAATG-3′ (forward) and 5′- CTGTCAACGATACGCTACG-3′ (reverse); U6: 5′-CTCGCTTCGGCAGCACATATACT-3′ (forward) and 5′-ACGCTTCACGAATTTGCGTGTC-3′ (reverse).

**Cell culture and treatment**

Human cardiomyocyte cell line (AC-16) obtained from BeNa Culture Collection (Beijing, China) was cultured in DMEM containing 10% FBS in an incubator with 5% CO2 at 37°C. To construct an in vitro SICD model (LPS-induced cell model), AC16 cells were exposed to 100 ng/ml LPS for 24 h [24].

**Cell transfection**

Short interfering RNA (siRNA) against LINC00472 (si-LINC00472), YY1 (si-YY1), negative control (si-NC), pcDNA3.1/LINC00472 vector (oe-LINC00472), pcDNA3.1/MAOA vector (oe-MAOA), pcDNA3.1/YY1 vector (oe-YY1), pcDNA3.1 empty vector (Vector), miR-335-3p mimics, miR-335-3p inhibitor, and their respective negative controls (NC inhibitor and NC mimics) were synthesized by GenePharma (Shanghai, China). Cells were transfected with these plasmids via Lipofectamine 2000 (Invitrogen) and collected for subsequent experiments after 24 hours’ incubation.

**CCK-8**

Cells were plated into 96-well plates (5 × 10⁴ cells/well) and cultivated for 24 hours. Then, 10 μL CCK-8 solution was supplemented to each well. After 2 hours’ incubation, the absorbance at 450 nm wavelength was detected with a Microplate Reader (Thermofisher) [25].

**Flow cytometry**

Concerning cell apoptosis detection, cells were harvested and then dyed with Annexin V-FITC and PI. Thereafter, the cells were incubated in darkness for 20 minutes at room temperature. The apoptosis rate was assessed via flow cytometry (BD Biosciences, USA) [26]. The sum of the upper-right (Q2) and lower-right (Q3) quadrants represents total apoptosis percentage. The upper-left (Q1) quadrant is the percentage of necrosis and lower-left (Q2) quadrant corresponds to viable cells.

**ChIP assay**

Following the standard protocol of ChIP Assay Kit (Millipore), the binding condition between YY1 and LINC00472 promoter was verified. Firstly, Cells were treated with formaldehyde to produce cross-linked chromatin. Afterward, sonication was applied to generate 200–300 bp chromatin fragments. Then, immunoprecipitation on chromatin fragments was performed with YY1 or IgG antibodies (Abcam, USA). The DNA fragments were purified, recuperated, and subjected to RT-qPCR analysis after incubation with Dynabeads Protein G (Life Technologies, USA) [27].

**Dual-luciferase reporter assay**

To confirm the relationship between YY1 and LINC00472, two different fragment sequences of LINC00472 promoter containing putative YY1-binding sites (E1, E2 and E3) were synthesized and inserted into pmirGLO luciferase vector: pmirGLO-E1+ E3 (P1) and pmirGLO-E1+ E2 + E3 (PF). Then, cells were co-transfected with P1 or PF and oe-YY1 (or Vector). To examine the relationship between miR-335-3p and LINC00472 or MAOA, cells were transfected with wildtype (WT) or mutant (MUT) LINC00472 (LINC00472-WT or LINC00472-MUT) or MAOA (MAOA-WT or MAOA-MUT) luciferase vectors, together with miR-335-3p.
mimics or NC mimics. Luciferase reporter assay was conducted on Dual-Luciferase® Reporter Assay System (Promega, USA) after 48 hours’ incubation [28].

**RNA immunoprecipitation (RIP) assay**

The EZMagna RIP kit (Millipore, USA) was utilized for RIP assay in this study. Firstly, the cells were lysed in RIP lysis buffer. Subsequently, the lysates were incubated with magnetic beads conjugated with specific antibodies or control IgG (Millipore). Then, the beads were rinsed and incubated with Proteinase K for protein removal. Finally, purified RNA was collected for further RT-qPCR analysis [29].

**Statistical analyses**

In our study, data were obtained from three independent experiments and expressed as mean ± standard deviation (SD). Via GraphPad Prism 6.0 software, comparisons between two or more groups were carried out with two-tailed Student’s t-test or one-way ANOVA. P-value<0.05 was confirmed significant in statistics.

**Results**

In this study, we aimed to investigate the regulatory role of LINC00472 in sepsis-associated cardiac dysfunction and the potential mechanism involved. Through certain functional assays and bioinformatic investigations, we found YY1-stimulated LINC00472 exacerbated LPS-induced cardiomyocyte dysfunction by targeting the miR-335-3p/MAOA pathway, offering a potential target for SICD treatment.

**Upregulated LINC00472 expression was observed in the in vivo SICD model**

To investigate the functions of LINC00472 in SICD, a murine SICD model was established by LPS treatment. As indicated by H&E staining results, compared with Sham group, the arrangement of murine myocardial muscle fibers was disordered in LPS group; moreover, myocardium swelling and interstitial edema were also observed in LPS group (Figure 1(a)). In addition, serum cTnI and CK-MB levels were increased in LPS-induced mice (Figure 1(b,c)). Besides, the production of inflammatory cytokines (TNF-α and IL-1β) was enhanced in myocardial tissues from LPS

![Figure 1](image_url)

**Figure 1.** Upregulated LINC00472 expression was observed in the in vivo SICD model. (a) The myocardial structure of mice was observed via H&E staining. (b and c) The cTnI (b) and CK-MB (c) levels in mouse serum were measured with ELISA. (d and e) TNF-α (d) and IL-1β (e) expression levels in serum samples from mice were detected by ELISA. (f) The expression levels of apoptosis-associated proteins (Bcl-2 and cleaved Caspase-3) were detected by Western blotting. (g) LINC00472 expression in myocardial tissue of mice from Sham group and LPS group was detected by RT-qPCR. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
group (Figure 1(d,e)). Also, Western blotting assay revealed that cleaved caspase-3 levels were increased, while Bcl-2 level was declined in myocardial tissue from LPS group, relative to the Sham group (Figure 1(f)). Interestingly, a substantial upregulation of LINC00472 expression was also found in myocardium from LPS mice, relative to Sham mice (Figure 1(g)), indicating the potential involvement of LINC00472 in the regulation of apoptosis and inflammatory response in SICD.

**LINC00472 knockdown alleviates LPS-induced cardiac dysfunction in vitro**

In order to explore the functional significance and molecular mechanism of LINC00472 in SICD, especially, cardiomyocyte viability, apoptosis and inflammation, the human cardiomyocyte cell line (AC-16) was utilized to establish the in vitro SICD cell model via LPS treatment. CCK-8 assay showed that LPS remarkably reduced AC-16 cardiomyocyte viability (Figure 2(a)). Consistent with the observed results from the in vivo model, TNF-α and IL-1β levels were substantially increased after LPS treatment (Figure 2(b,c)). In addition, LINC00472 expression in AC-16 cells was also lifted significantly following LPS administration (Figure 2(d)). Then, the efficiency of LINC00472 knockdown in AC-16 cardiomyocytes was verified by RT-qPCR (Figure 2(e)). It was found that LINC00472 depletion eliminated the inhibition on AC-16 cell viability mediated by LPS treatment and suppressed LPS-induced AC-16 cell apoptosis and inflammatory response (Figure 2(f-i)). Taken together, these data suggested that LINC00472 essentially regulated LPS-mediated cardiomyocyte viability, apoptosis, and inflammatory response.

![Figure 2. LINC00472 knockdown alleviates LPS-induced cardiac dysfunction in vitro.](image-url)

(a) The viability of AC-16 cardiomyocytes was measured by CCK-8 assay. (b and c) Levels of TNF-α (b) and IL-1β (c) in the supernatants were measured by ELISA. (d) LINC00472 expression in AC-16 cells from Control group and LPS group was detected by RT-qPCR. (e) RT-qPCR analysis was used to assess the transfection efficiency of LINC00472 knockdown. (f) CCK-8 assay was adopted to detect the viability of AC-16 cardiomyocytes from Control group, LPS group, LPS+si-NC group, or LPS+si-LINC00472 group, respectively. (g) Flow cytometry was performed to detect AC-16 cardiomyocyte in each group. (h and i) TNF-α (h) and IL-1β (i) expression levels in the supernatants from each group were detected by ELISA. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
YY1 transcriptionally activates LINC00472

By the JASPAR database detection, three YY1 binding sites (E1, E2, and E3) with scores > 7 were identified in the promoter region of LINC00472 (Figure 3(a)). ChIP assay showed that YY1 was specifically bound to E2 region of LINC00472 gene (Figure 3(b)). To further confirm the transcriptional activation of LINC00472 by YY1, YY1 was first knocked down or overexpressed in AC-16 cells (Figure 3(c)). Consistently, luciferase reporter assay exhibited that YY1 substantially activated the luciferase activity driven by LINC00472 promoter sequence containing E2 (Figure 3(d)). As indicated by RT-qPCR, YY1 expression was significantly higher in LPS-challenged myocardium and cardiomyocytes, compare with normal myocardial tissues and cardiomyocytes (Figure 3(e,f)). Besides, LINC00472 transcription was increased after YY1 upregulation and decreased after YY1 knockdown in AC-16 cells (Figure 3(g)). In addition, YY1 inhibition partly reversed the effect of LPS treatment on LINC00472 abundance in AC-16 cells (Figure 3(h)). To sum up, these results indicated that YY1 directly promoted LINC00472 transcription during SICD progression.

Figure 3. YY1 transcriptionally activates LINC00472. (a) The potential YY1-binding motifs within LINC00472 promoter which consist of E1, E2 and E3 regions was predicted by JASPAR. (b) YY1 affinity in the promoter region of LINC00472 was assessed by ChIP assay. (c) RT-qPCR analysis was used to assess the transfection efficiency of YY1 overexpression and knockdown. (d) Luciferase reporter assay was performed by co-transfecting the full LINC00472 promoter (PF), deleted LINC00472 promoter fragment E2 (P1) or single E2 fragment (P2) into AC-16 cells, together with oe-YY1 or Vector. (e) YY1 expression in myocardial tissue of mice from Sham group and LPS group was detected by RT-qPCR. (f) YY1 expression in AC-16 cells from Control group and LPS group was detected by RT-qPCR. (g) LINC00472 expression in cardiomyocytes transfected with si-NC, si-YY1, Vector, or oe-YY1, respectively. (h) LPS-challenged AC-16 cardiomyocytes were transfected with si-NC, si-YY1, Vector, or oe-YY1, respectively. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
**YY1-induced LINC00472 upregulation promotes LPS-induced cardiomyocyte dysfunction**

To explore the relationship between YY1 and LINC00472, the relative functional assays were implemented. First of all, LINC00472 was overexpressed in AC-16 cells (Figure 4(a)). Then, LPS-challenged AC-16 cardiomyocytes were transfected with si-NC, si-YY1, or si-YY1+ oe-LINC00472. RT-qPCR assay exhibited that LINC00472 expression was decreased after YY1 blocking and increased after LINC00472 overexpression (Figure 4(b)). CCK-8 results implicated that the enhanced LPS-

![Figure 4](image-url)

**Figure 4.** YY1-induced LINC00472 upregulation promotes LPS-induced cardiomyocyte dysfunction. (a) RT-qPCR analysis was used to assess the transfection efficiency of LINC00472 overexpression. (b) LPS-challenged AC-16 cardiomyocytes were transfected with si-NC, si-YY1, or si-YY1+ oe-LINC00472. RT-qPCR was utilized to detect LINC00472 expression in AC-16 cardiomyocytes from each group. (c) CCK-8 assay was adopted to detect the viability of AC-16 cardiomyocytes in each group. (d) Flow cytometry was performed to detect AC-16 cardiomyocyte in each group. (e and f) TNF-α (e) and IL-1β (f) expression levels in the supernatants from each group were detected by ELISA. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
induced AC-16 cardiomyocyte viability mediated by YY1 knockdown was rescued by LINC00472 upregulation (Figure 4(c)). Then, flow cytometry assay disclosed that YY1 depletion reduced the apoptotic rate of LPS-treated AC-16 cells, which was partially abrogated by LINC00472 overexpression (Figure 4(d)). In addition, LINC00472 upregulation partially reversed the suppressive effect of YY1 silencing on the production of TNF-α and IL-1β (Figure 4(e,f)). Henceforth, YY1-mediated upregulation of LINC00472 facilitates LPS-induced cardiac dysfunction in vitro.

**LINC00472 interacts with miR-335-3p**

Next, the downstream mechanism of LINC00472 on the regulation of AC-16 cardiomyocyte viability, apoptosis, and inflammatory response was further investigated. DIANA website predicted miR-335-3p as a target of LINC00472 (Figure 5(a)). Then, the miR-335-3p overexpression efficiency was detected by RT-qPCR (Figure 5(b)). Subsequently, luciferase reporter assay indicated that the luciferase activity of LINC00472-WT weakened after co-transfection with miR-335-3p mimics (Figure 5(c)). RIP assay further confirmed the coexistence of LINC00472 and miR-335-3p in RISC (Figure 5(d)), suggesting the potential interaction between LINC00472 and miR-335-3p. RT-qPCR results revealed that miR-335-3p expression was markedly down-regulated in both in vivo and in vitro SCID models (Figure 5(e,f)), implying an inverse correlation between miR-335-3p and LINC00472. According to RT-qPCR results, miR-335-3p expression in LPS-induced AC-16 cells was increased after LINC00472 knockdown and decreased after LINC00472 overexpression (Figure 5(g)). Therefore, these data indicated that LINC00472 negatively regulated miR-335-3p expression in LPS-treated AC-16 cardiomyocytes.

**Figure 5.** LINC00472 interacts with miR-335-3p. (a) The potential binding site between LINC00472 and miR-335-3p. (b) RT-qPCR analysis was used to assess the transfection efficiency of miR-335-3p overexpression. (c) The binding condition between LINC00472 and miR-335-3p was validated by dual-luciferase report assay. (d) Existence of LINC00472 and miR-335-3p in RISC was determined with RIP assay. (e) The miR-335-3p expression in myocardial tissue of mice from Sham group and LPS group was detected by RT-qPCR. (f) The miR-335-3p expression in AC-16 cells from Control group and LPS group was detected by RT-qPCR. (g) LPS-challenged AC-16 cardiomyocytes were transfected with si-NC, si-LINC00472, Vector, or oe-LINC00472, with untreated AC-16 cells as the control group. The miR-335-3p expression in AC-16 cells from each group. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
**LINC00472 regulates MAOA via interaction with miR-335-3p**

Subsequently, the downstream molecular mechanism of miR-335-3p was analyzed. Monoamine oxidase A (MAOA) was identified as an upregulated mRNA in sepsis according to a previous report by Qin et al. [30]. TargetScan website also predicted MAOA as a potential target of miR-335-3p (Figure 6(a)). Subsequently, the luciferase reporter assay verified the binding condition between miR-335-3p and MAOA (Figure 6(b)). RT-qPCR results revealed that MAOA mRNA expression was significantly upregulated in LPS-challenged mice (Figure 6(c)). Similarly, MAOA mRNA and protein expressions were substantially elevated in AC-16 cardiomyocytes (Figure 6(d)). These results were consistent with LINC00472 but opposite to miR-335-3p. Then, miR-335-3p expression was suppressed via miR-335-3p inhibitor (Figure 6(e)). As revealed by RT-qPCR and Western blotting assays, MAOA mRNA and protein expressions were reduced after miR-335-3p upregulation and increased after miR-335-3p downregulation (Figure 6(f)). Moreover, MAOA mRNA and protein expressions were significantly

![Figure 6. LINC00472 regulates MAOA via interaction with miR-335-3p. (a) The potential binding site between MAOA and miR-335-3p. (b) The binding condition between MAOA and miR-335-3p was validated by dual-luciferase report assay. (c) The MAOA mRNA expression in myocardial tissue of mice from Sham group and LPS group was detected by RT-qPCR. (d) The MAOA mRNA and protein expressions in AC-16 cells from Control group and LPS group were detected by RT-qPCR and Western blotting. (e) RT-qPCR analysis was used to assess the transfection efficiency of miR-335-3p inhibition. (f) LPS-challenged AC-16 cardiomyocytes were transfected with NC inhibitor, miR-335-3p inhibitor, NC mimics, or miR-335-3p mimics. The MAOA mRNA and protein expressions in AC-16 cells from each group were detected by RT-qPCR and Western blotting. (g) LPS-challenged AC-16 cardiomyocytes were transfected with si-NC, si-LINC00472, si-LINC00472+ NC inhibitor, or si-LINC00472+ miR-335-3p inhibitor. The MAOA mRNA and protein expressions in AC-16 cells from each group were detected by RT-qPCR and Western blotting. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.](image-url)
reduced after LINC00472 knockdown, whereas the results were partly abolished by miR-335-3p inhibition (Figure 6(g)). Thus, it was verified that LINC00472 positively regulated MAOA expression via interaction with miR-335-3p.

**MiR-335-3p inhibition or MAOA overexpression reverses the improvement of AC-16 cardiomyocyte functions induced by LINC00472 knockdown**

To thoroughly explore the regulatory function of the LINC00472/miR-335-3p/MAOA network, a series of rescue experiments were performed. First, MAOA was overexpression efficiency in AC-16 cells was detected via RT-qPCR (Figure 7(a)). CCK-8 assay showed that the promotion on AC-16 cardiomyocyte viability by LINC00472 inhibition was reversed by miR-335-3p inhibition or MAOA overexpression (Figure 7(b)). Then, flow cytometry assay revealed that miR-335-3p suppression or MAOA upregulation could partly offset the inhibitory effect of LINC00472 knockdown on AC-16 cell apoptosis (Figure 7(c)). ELISA assay revealed that LINC00472 silencing suppressed the production of TNF-α and IL-1β, while miR-335-3p inhibition or MAOA overexpression partially abrogated such an effect (Figure 7(d,e)). Therefore, the above findings proved LINC00472 promoted AC-16 cardiomyocyte dysfunction via the miR-335-3p/MAOA axis.

**Discussion**

SICD is a kind of severe septic complication with a high mortality rate [31]. Although some studies have confirmed lncRNAs as vital regulators for cellular processes in SICD [32], the regulatory functions and specific mechanisms of LINC00472 in SICD remain vague. Ye et al. revealed that LINC00472 attenuated colorectal cancer by

---

**Figure 7.** MiR-335-3p inhibition or MAOA overexpression reverses the improvement of AC-16 cardiomyocyte functions induced by LINC00472 knockdown. (a) The efficiency of MAOA overexpression was tested by RT-qPCR analysis. (b) LPS-challenged AC-16 cardiomyocytes were transfected with si-NC, si-LINC00472, si-LINC00472+ miR-335-3p inhibitor, or si-LINC00472+ oe-MAOA. CCK-8 assay was adopted to detect the viability of AC-16 cardiomyocytes in each group. (c) Flow cytometry was performed to detect AC-16 cardiomyocyte viability in each group. (d and e) TNF-α (d) and IL-1β (e) expression levels in the supernatants from each group were detected by ELISA. All data were performed at least three independent experiments. Data were expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
inhibiting cell proliferation and promoting apoptosis via the miR-196a/PDCD4 pathway [33]. Zhang et al. disclosed that LINC00472 suppressed osteosarcoma cell proliferation by regulating FOXO1 via interaction with miR-300 [34]. Also, Li et al. found LINC00472 promoted inflammatory response in sepsis-induced acute hepatic injury by targeting TRIM8 via miR-373-3p [18]. In this work, LINC00472 level was upregulated in both in vivo and in vitro SICD models. Consistent with the above findings, LPS treatment inhibited cardiomyocyte viability and promoted apoptosis and inflammatory responses of cardiomyocytes, while LINC00472 knockdown partly reversed the effect caused by LPS.

As demonstrated by previous studies, (Yin-Yang 1) YY1 transcription factor could act as a transcriptional activator for numerous lncRNAs [35]. YY1 is deeply involved in the regulation of diverse cellular activities, including proliferation, apoptosis, and inflammatory response [36–38]. In addition, a former study disclosed that YY1-activated ST2 upregulation contributed to worse cardiac remodeling after myocardial infarction [39], indicating its engagement in cardiac disorders. In this study, Consistently, we identified YY1 as an upstream regulator which transcriptionally activated LINC00472 expression, thus promoting the cardiomyocyte dysfunction induced by LPS.

In sepsis, via a competitive endogenous RNA (ceRNA) network, the lncRNA regulates mRNA expression via interaction with miRNA, thereby affecting cellular activities [40]. Previous studies have been proven that miRNAs are also deeply complicated in SICD development and progression [41]. Gao et al. demonstrated that miR-335-3p could relieve the inflammatory responses in a murine sepsis model [42]. However, the relationship between miR-335-3p and SICD is still obscure. A variety of studies have elaborated on the essential role of miR-335-3p in regulating cell proliferation, cell apoptosis, and inflammatory responses in human diseases. For example, Oliveira et al. reported that miR-335-3p could relieve inflammatory responses in Parkinson’s Disease via regulating LRRK2 [43]. We et al. demonstrated that miR-335-3p could alleviate the inhibitory effect of oxygen-glucose deprivation/reperfusion treatment on primary neuron proliferation [44]. Also, Yu et al. revealed that miR-335-3p could inhibit the apoptosis of nucleus pulposus cells [45]. In this study, it was disclosed that miR-335-3p was expressed lowly in both in vivo and in vitro SICD models. LINC00472 negatively regulated miR-335-3p in LPS-challenged cardiomyocytes. More importantly, the impact of LINC00472 silencing on the cardiomyocyte dysfunction induced by LPS could be partly reversed by miR-335-3p inhibition.

Similarly, MAOA was also identified as a downstream target of miR-335-3p in this work. MAOA exerts crucial effects on cardiac disorders. To cite an instance, Umbarkar et al. found that MAOA induced cardiac dysfunction in diabetic cardiomyopathy [46]. In addition, Pallio et al. revealed that metaxalone-induced MAOA knockdown could relieve inflammatory responses in microglial cells activated by IL-1β [47], indicating the proinflammatory effect of MAOA. Herein, MAOA expression was significantly elevated in both in vivo and in vitro SICD models. Besides, MAOA expression in LPS-induced cardiomyocytes was negatively regulated by miR-335-3p and positively regulated by LINC00472. Moreover, MAOA overexpression abolished the effect of LINC00472 depletion on LPS-induced cardiomyocyte dysfunction. Based on all these results, it was summarized that LINC00472 promoted SCID progression in vitro by positively regulating MAOA expression via interaction with miR-335-3p.

**Conclusion**

In summary, our findings proved that LINC00472, which is induced by YY1, could impair cardiomyocyte viability and facilitate apoptosis and inflammatory response in LPS-challenged cardiomyocytes via the miR-335-3p/MAOA axis. These findings could provide novel biomarkers for further research and development of SICD treatment strategies. However, this study still has some limitations. For example, the YY1/LINC00472/miR-335-3p/MAOA regulatory network in SICD was mainly verified through cytological experiments rather than animal studies. In the future, this molecular mechanism will be further affirmed via in vivo studies.
Research highlights

(1) LINC00472 expression was elevated in both in vivo and vitro SICD models.
(2) LINC00472 knockdown alleviated LPS-induced cardiomyocyte dysfunction.
(3) YY1-induced LINC00472 upregulation promotes LPS-induced cardiomyocyte dysfunction.
(4) LINC00472 upregulated MAOA level via interaction with miR-335-3p.
(5) LINC00472 improved LPS-induced AC-16 cell dysfunction by miR-335-3p/MAOA axis.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
The author(s) reported there is no funding associated with the work featured in this article.

ORCID
Yijun Liu http://orcid.org/0000-0002-3544-8302

References
[1] Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues. Am Surg. 2012;78(1):3–8.
[2] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.
[3] Bunnell E, Parrillo JE. Cardiac dysfunction during septic shock. Clin Chest Med. 1996;17(2):237–248.
[4] Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
[5] Kakihana Y, Ito T, Nakahara M, et al. Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care. 2016;4(1):22.
[6] Liu JJ, Li Y, Yang M-S, et al. SP1-induced ZFAS1 aggravates sepsis-induced cardiac dysfunction via miR-590-3p/NLRP3-mediated autophagy and pyroptosis. Arch Biochem Biophys. 2020;695:108611.
[7] Lu Y, Yang Y, He X, et al. Esmolol reduces apoptosis and inflammation in early sepsis rats with abdominal infection. Am J Emerg Med. 2017;35(10):1480–1484.
[8] Sergi C, Shen F, Lim DW, et al. Cardiovascular dysfunction in sepsis at the Dawn of emerging mediators. Biomed Pharmacother. 2017;95:153–160.
[9] Luo M, Yan D, Sun Q, et al. Ginsenoside Rgl1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4/NF-κB/NLRP3 pathway. J Cell Biochem. 2020;121(4):2994–3004.
[10] Zhang WX, He B-M, Wu Y, et al. Melatonin protects against sepsis-induced cardiac dysfunction by regulating apoptosis and autophagy via activation of SIRT1 in mice. Life Sci. 2019;217:8–15.
[11] Li P, Chen X-R, Xu F, et al. Alamandine attenuates sepsis-associated cardiac dysfunction via inhibiting MAPKs signaling pathways. Life Sci. 2018;206:106–116.
[12] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–159.
[13] Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochim J. 2012;441(2):106–116.
[14] Mathy NW, Chen XM. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem. 2017;292(30):12375–12382.
[15] Sun F, Yuan W, Wu H, et al. LncRNA KCNQ1OT1 attenuates sepsis-induced myocardial injury via regulating miR-192-5p/XIAP axis. Exp Biol Med (Maywood). 2020;245(7):620–630.
[16] Chen T, Zhu C, Ye C. LncRNA CYTOR attenuates sepsis-induced myocardial injury via regulating miR-24/XIAP. Cell Biochem Funct. 2020;38(7):976–985.
[17] Shan B, Li J-Y, Liu Y-J, et al. LncRNA H119 Inhibits the Progression of Sepsis-Induced Myocardial Injury via Regulation of the miR-93-5p/SORBS2 Axis. Inflammation. 2021;44(1):344–357.
[18] Li L, He Y, He X-J, et al. Down-regulation of long noncoding RNA LINCO0472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis. Exp Mol Pathol. 2020;117:104562.
[19] Wu H, Liu, J, Li, W, et al. LncRNA-HOTAIR promotes TNF-alpha production in cardiomyocytes of LPS-induced sepsis mice by activating NF-kappaB pathway. Biochem Biophys Res Comm. 2016;471(1):240–246.
[20] Xu S, Wu B, Zhong B, et al. Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis. Bioengineered. 2021;12(2):10924–10934.
[21] Li J, Deng Q, Fan W, et al. Melatonin-induced suppression of DNA methylation promotes odontogenic differentiation in human dental pulp cells. Bioengineered. 2020;11(1):829–840.
[22] Hu X, Chen J, Huang H, et al. Syndecan-4 promotes vascular beds formation in tissue engineered liver via thrombospondin 1. Bioengineered. 2020;11(1):1313–1324.
[23] Yu L, Gong, X, Sun, L, et al. The Circular RNA Cdr1as Act as Targeting an Oncogene in Hepatocellular Carcinoma through Targeting miR-7 Expression. PloS One. 2016;11(7):e0158347.

[24] Tan J, Zhou X, Huang X, et al. FAM46C inhibits lipopolysaccharides-induced myocardial dysfunction via downregulating cellular adhesion molecules and inhibiting apoptosis. Life Sci. 2019;217:229.

[25] Yao Y, Li X, Cheng L, et al. Circular RNA FAT atypical cadherin 1 (circFAT1)/miRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway. Bioengineered. 2021;12(1):4032–4043.

[26] Guohua H, Hongyang L, Zhiming J, et al. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs. Biosens Bioelectron. 2017;97:184–195.

[27] Zhang M, Xu Y, Yin S, et al. YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoposis of bladder cancer cells via regulating programmed cell death-ligand 1. Bioengineered. 2021;12(2):9150–9161.

[28] Zhang Y, Zhang Y, Wang S, et al. SP1-induced IncRNA ZFPM2 antisense RNA 1 (ZFPM2-AS1) aggravates glioma progression via the miR-515-5p/Superoxide dismutase 2 (SOD2) axis. Bioengineered. 2021;12(1):2299–2310.

[29] Long H, Li Q, Xiao Z, et al. LncRNA MIR22HG promotes osteoarthritis progression via regulating miR-9-3p/ADAMTS5 pathway. Bioengineered. 2021;12(1):3148–3158.

[30] Qin Y, Guo X, Yu Y, et al. Screening key genes and microRNAs in sepsis by RNA-sequencing. J Chin Med Assoc. 2020;83(1):41–47.

[31] Essandoh K, Wang, X, Huang, W, et al. Tumor susceptibility gene 101 ameliorates endotoxin-induced cardiac dysfunction by enhancing Parkin-mediated mitophagy. J Biol Chem. 2019;294(48):18057–18068.

[32] Wang X, Li X-L, Qin L-J. The IncRNA XIST/miR-150-5p/c-Fos axis regulates sepsis-induced myocardial injury via TXNIP-modulated pyroptosis. Lab Invest. 2021;101(9):1118–1129.

[33] Ye Y, Yang, S, Han, Y, et al. Linc00472 suppresses proliferation and promotes apoptosis by elevating PDCD4 expression by sponging miR-196a in colorectal cancer. Aging (Albany NY). 2018;10(6):1523–1533.

[34] Zhang J, Zhang J, Zhang D, et al. Down-regulation of LINC00472 promotes osteosarcoma tumorigenesis by reducing FOXO1 expressions via miR-300. Cancer Cell Int. 2020;20(1):100.

[35] Huang T, Wang G, Yang L, et al. Transcription Factor YY1 Modulates Lung Cancer Progression by Activating lncRNA-PVT1. DNA Cell Biol. 2017;36(11):947–958.

[36] Han D, Zhou Y. YY1-induced upregulation of IncRNA NEAT1 contributes to OGD/R injury-induced inflammatory response in cerebral microglial cells via Wnt/beta-catenin signaling pathway. In Vitro Cell Dev Biol Anim. 2019;55(7):501–511.

[37] Sun M, Zhai L, Liu H, et al. Downregulation of IncRNA ZFAS1 inhibits the hallmarks of thyroid carcinoma via the regulation of miR-302-3p on cyclin D1. Mol Med Rep. 2021;23(1):2.

[38] Lin J, He Y, Chen J, et al. A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6. J Autoimmun. 2017;77:67–75.

[39] Asensio-Lopez MC, Lax A, Fernandez Del Palacio MJ, et al. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. J Mol Cell Cardiol. 2019;130:216–233.

[40] Guo X, Qin, Y, Wang, L, et al. A competing endogenous RNA network reveals key IncRNAs associated with sepsis. Mol Genet Genomic Med. 2021;9(1):e1557.

[41] Manetti AC, Maiese A, Paolo MD, et al. MicroRNAs and Sepsis-Induced Cardiac Dysfunction: a Systematic Review. Int J Mol Sci. 2020;22(1):1.

[42] Gao X-L, Li J-Q, Dong Y-T, et al. Upregulation of microRNA-335-5p reduces inflammatory responses by inhibiting FASN through the activation of AMPK/ULK1 signaling pathway in a septic mouse model. Cytokine. 2018;110:466–478.

[43] Oliveira SR, Dionisio PA, Gaspar MM, et al. miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson’s Disease. Front Cell Dev Biol. 2021;9:661461.

[44] Wu F, Han B, Wu S, et al. Circular RNA TLK1 Aggravates Neuronal Injury and Neurological Deficits after Ischemic Stroke via miR-335-3p/TIPARP. J Neurosci. 2019;39(37):7369–7393.

[45] Yu L, Hao Y, Xu C, et al. LINCO0969 promotes the hallmarks of thyroid cancer through Targeting miR-7 Expression. PloS One. 2020;15(10):e0238529.

[46] Pallio G, D’Ascola A, Cardia L, et al. MAO-A inhibits YY1-induced upregulation of IncRNA ZFPM2 antisense RNA 1 (ZFPM2-AS1) aggravates glioma progression via the miR-515-5p/Superoxide dismutase 2 (SOD2) axis. Bioengineered. 2021;12(1):2299–2310.

[47] Umbarkar P, Singh, S, Arkat, S, et al. Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy. Free Radic Biol Med. 2015;87:263–273.

[48] Pallio G, D’Ascola A, Cardia L, et al. MAO-A inhibition by metaxalone reverts IL-1beta-induced inflammatory phenotype in microglial cells. Int J Mol Sci. 2021;22(16):16.